Matrix-M
Commercial- Indications
- Vaccine adjuvant
Company intelligence / Profile preview
Isconova AB
Uppsala, Uppsala County, Swedenen.wikipedia.org ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Isconova developed proprietary nano-particle-based adjuvant technologies that enhance the efficacy of vaccines. Its Matrix-M™ adjuvant was used in several clinical-stage vaccine candidates and is commercially available in veterinary products. The company had multiple partnerships with leading pharma/biotech firms and academic groups. In 2013 it was acquired by Novavax Inc., which integrated its platform into Novavax’s pipeline[2][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccine adjuvants (not direct therapeutics, but enabling technology for vaccines)Nano-particle based adjuvants (Matrix-M™, ISCOM, Posintro™)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Isconova AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isconova AB.